Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, quantitative, competitive reverse transcription polymerase chain reaction (QC-RT-PCR) analysis demonstrated that Ad21 could effectively reduce DU 145 and erbB-2-positive primary prostate tumor contamination in bone marrow cultures.
|
9017419 |
1997 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the role of oncogenes and growth factors in prostate carcinoma is still unclear, overexpression of the epidermal growth factor receptor (erbB-1) and the proto-oncogene erbB-2 have been reported in prostate tumors, and erbB-2 related to poor prognosis and distant metastasis.
|
9917515 |
1999 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Previous studies have reported widely divergent rates for HER2 expression in primary prostate tumors, probably owing to significant methodologic differences in the studies.
|
11488070 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Of the 31 prostate tumors in the untreated group 9 (29%) showed high HER-2/neu expression versus 15 of 30 (50%) in the treated and 17 of 20 (85%) in the androgen independent groups.
|
11547123 |
2001 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification.
|
11786427 |
2002 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To quantitate the level of ERBB2 mRNA expression in prostate tumors (n = 34) and cell lines (n = 3), as well as in breast tumors (n = 30) and cell lines (n = 16), real-time reverse transcriptase-polymerase chain reaction (LightCycler) methodology was used.
|
11786427 |
2002 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Of the 10 tumor samples analyzed by fluorescence in situ hybridization, genomic amplification of the Her-2/neu locus was not detected in any of the metastatic prostate tumors.
|
15269147 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Peripheral blood lymphocytes (PBL) were then isolated from six consecutive human leukocyte antigen (HLA) A2+ patients with HER2/neu+ prostate tumors.
|
15547716 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In order to define AR, erbB-1 and erbB-2 in human prostate neoplasms 36 benign prostatic hyperplasia, 46 prostatic carcinoma and 12 normal prostate gland samples were analysed.
|
14654929 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
|
15083213 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility.
|
15389808 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
|
17363613 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.
|
17704139 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients.
|
18038879 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells.
|
17563746 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors.
|
17192923 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
|
18767028 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
|
18337451 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy.
|
18645672 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways.
|
18324648 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis.
|
21930937 |
2011 |